Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

AbbVie’s Skyrizi tallied the most TV impressions among pharma brands in July, rising from second in June. The psoriasis treatment achieved a share of voice (SOV) of 4.61% with 2.5 billion impressions.

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

AbbVie ABBV reported second-quarter revenue of $15.4 billion (6.6% growth) and adjusted diluted earnings per share of $2.97 ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

AbbVie Inc reported a robust second quarter for 2025, with adjusted earnings per share of $2.97 and net revenues reaching $15 ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

AbbVie’s beat Wall Street’s estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and ...

AbbVie expects combined sales of Skyrizi and Rinvoq to be around $24.7 billion in 2025 and more than $31 billion by 2027.